Literature DB >> 25682596

High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia.

Lili Wu1, Yang Xu1, Qian Wang1, Changgeng Ruan1, Hans G Drexler2, Depei Wu1, Roderick A F MacLeod2, Suning Chen3.   

Abstract

Entities:  

Keywords:  LMO2; T-cell acute lymphoblastic leukemia; expression; rearrangement

Mesh：

Substances：

Year:  2015        PMID： 25682596      PMCID： PMC4450637          DOI： 10.3324/haematol.2014.120089

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Activation of HOX11L2 by juxtaposition with 3'-BCL11B in an acute lymphoblastic leukemia cell line (HPB-ALL) with t(5;14)(q35;q32.2).

Authors:  Roderick A F MacLeod; Stefan Nagel; Maren Kaufmann; Johannes W G Janssen; Hans G Drexler
Journal:  Genes Chromosomes Cancer       Date:  2003-05       Impact factor: 5.006

2.  The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2).

Authors:  Stefan Nagel; Maren Kaufmann; Hans G Drexler; Roderick A F MacLeod
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 3.  Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.

Authors:  Matthew P McCormack; Terence H Rabbitts
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

4.  Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.

Authors:  Stefan Nagel; Michaela Scherr; Alexander Kel; Klaus Hornischer; Gregory E Crawford; Maren Kaufmann; Corinna Meyer; Hans G Drexler; Roderick A F MacLeod
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

5.  The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Martine van Grotel; H Berna Beverloo; Charles Lee; Tryggvi Helgason; Jessica Buijs-Gladdines; Monique Passier; Elisabeth R van Wering; Anjo J P Veerman; Willem A Kamps; Jules P P Meijerink; Rob Pieters
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

6.  Novel non-TCR chromosome translocations t(3;11)(q25;p13) and t(X;11)(q25;p13) activating LMO2 by juxtaposition with MBNL1 and STAG2.

Authors:  S Chen; S Nagel; B Schneider; M Kaufmann; C Meyer; M Zaborski; U R Kees; H G Drexler; R A F MacLeod
Journal:  Leukemia       Date:  2011-06-07       Impact factor: 11.528

7.  A far downstream enhancer for murine Bcl11b controls its T-cell specific expression.

Authors:  Long Li; Jingli A Zhang; Marei Dose; Hao Yuan Kueh; Ruzbeh Mosadeghi; Fotini Gounari; Ellen V Rothenberg
Journal:  Blood       Date:  2013-06-05       Impact factor: 22.113

8.  Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.

Authors:  Elena Cubedo; Andrew J Gentles; Chuanxin Huang; Yasodha Natkunam; Shruti Bhatt; Xiaoqing Lu; Xiaoyu Jiang; Isabel Romero-Camarero; Aharon Freud; Shuchun Zhao; Carlos E Bacchi; Jose A Martínez-Climent; Isidro Sánchez-García; Ari Melnick; Izidore S Lossos
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

9.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

10.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.

Authors:  Steven J Howe; Marc R Mansour; Kerstin Schwarzwaelder; Cynthia Bartholomae; Michael Hubank; Helena Kempski; Martijn H Brugman; Karin Pike-Overzet; Stephen J Chatters; Dick de Ridder; Kimberly C Gilmour; Stuart Adams; Susannah I Thornhill; Kathryn L Parsley; Frank J T Staal; Rosemary E Gale; David C Linch; Jinhua Bayford; Lucie Brown; Michelle Quaye; Christine Kinnon; Philip Ancliff; David K Webb; Manfred Schmidt; Christof von Kalle; H Bobby Gaspar; Adrian J Thrasher
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808
View more
  3 in total

1.  T-ALL can evolve to oncogene independence.

Authors:  Hesham Abdulla; Anh Vo; Benjamin J Shields; Tenae J Davies; Jacob T Jackson; Raed Alserihi; Elizabeth M Viney; Tin Wong; Feng Yan; Nicholas C Wong; Lisa Demoen; David J Curtis; Warren S Alexander; Pieter Van Vlierberghe; Ross A Dickins; Matthew P McCormack
Journal:  Leukemia       Date:  2021-01-22       Impact factor: 11.528

2.  LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.

Authors:  Tatsuya Morishima; Ann-Christin Krahl; Masoud Nasri; Yun Xu; Narges Aghaallaei; Betül Findik; Maksim Klimiankou; Malte Ritter; Marcus D Hartmann; Christian Johannes Gloeckner; Sylwia Stefanczyk; Christian Lindner; Benedikt Oswald; Regine Bernhard; Karin Hähnel; Ursula Hermanutz-Klein; Martin Ebinger; Rupert Handgretinger; Nicolas Casadei; Karl Welte; Maya Andre; Patrick Müller; Baubak Bajoghli; Julia Skokowa
Journal:  Blood       Date:  2019-07-31       Impact factor: 22.113

Review 3.  LMO2 at 25 years: a paradigm of chromosomal translocation proteins.

Authors:  Jennifer Chambers; Terence H Rabbitts
Journal:  Open Biol       Date:  2015-06       Impact factor: 6.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.